+

WO2002031168A3 - Vaccins de recombinaison a mediation par adenovirus minimal - Google Patents

Vaccins de recombinaison a mediation par adenovirus minimal

Info

Publication number
WO2002031168A3
WO2002031168A3 PCT/US2001/031842 US0131842W WO0231168A3 WO 2002031168 A3 WO2002031168 A3 WO 2002031168A3 US 0131842 W US0131842 W US 0131842W WO 0231168 A3 WO0231168 A3 WO 0231168A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
minimal
helper
hpv
hiv
Prior art date
Application number
PCT/US2001/031842
Other languages
English (en)
Other versions
WO2002031168A2 (fr
Inventor
Xiangming Fang
Scott Gallichan
Wei-Wei Zhang
Flossie Wong-Staal
Sybille Sauter
Original Assignee
Genstar Therapeutics
Xiangming Fang
Scott Gallichan
Wei-Wei Zhang
Flossie Wong-Staal
Sybille Sauter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genstar Therapeutics, Xiangming Fang, Scott Gallichan, Wei-Wei Zhang, Flossie Wong-Staal, Sybille Sauter filed Critical Genstar Therapeutics
Priority to AU2002211654A priority Critical patent/AU2002211654A1/en
Publication of WO2002031168A2 publication Critical patent/WO2002031168A2/fr
Publication of WO2002031168A3 publication Critical patent/WO2002031168A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à des vecteurs adénoviraux (Ad) et à leurs applications dans le domaine de la médecine génétique et notamment, mais pas exclusivement, en vaccination génique, en transfert génique, en thérapie génique et analogue. L'invention se rapporte plus spécifiquement à des vecteurs adénoviraux qui portent l'élément cis minimal du génome de l'adénovirus (vecteur Ad minimal) et qui sont capables de délivrer de 36 kb environ à 38 kb environ d'ADN hétérologue. La génération et la propagation des vecteurs Ad minimaux nécessitent une complémentation trans d'un adénovirus assistant (assistant), atténué par encapsidation et défectif s'agissant de sa réplication, dans une lignée de cellules T auxiliaires d'adénovirus. L'invention se rapporte également à des vecteurs adénoviraux minimaux pouvant être utilisés pour le traitement ou la prévention de maladies ou d'états pathologiques, à des méthodes de génération de tels vecteurs et à des systèmes d'essai sur des animaux permettant une évaluation in vivo de ces vecteurs adénoviraux. Plus spécifiquement, l'invention se rapporte à des vecteurs adénoviraux du VIH et/ou du papillomavirus (HPV) qui contiennent des éléments cis minimaux du génome de l'adénovirus et comprennent une séquence d'acide nucléique du VIH et/ou HPV comportant approximativement jusqu'à 36 à 38 kb d'éléments d'acide nucléique de support et/ou de complémentation. L'adénovirus minimal du VIH et/ou HPV peut être généré et de préférence amplifié grâce à l'aide de l'adénovirus assistant atténué par encapsidation et d'une lignée de cellules T auxiliaire. Cette invention se rapporte également à des procédés de conception de tels vecteurs adénoviraux minimaux et à des procédés permettant de tester ces vecteurs in vivo.
PCT/US2001/031842 2000-10-10 2001-10-10 Vaccins de recombinaison a mediation par adenovirus minimal WO2002031168A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002211654A AU2002211654A1 (en) 2000-10-10 2001-10-10 Minimal adenoviral vector and recombinant vaccines based thereon

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23922400P 2000-10-10 2000-10-10
US60/239,224 2000-10-10
US24162500P 2000-10-19 2000-10-19
US60/241,625 2000-10-19

Publications (2)

Publication Number Publication Date
WO2002031168A2 WO2002031168A2 (fr) 2002-04-18
WO2002031168A3 true WO2002031168A3 (fr) 2003-04-17

Family

ID=26932381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031842 WO2002031168A2 (fr) 2000-10-10 2001-10-10 Vaccins de recombinaison a mediation par adenovirus minimal

Country Status (2)

Country Link
AU (1) AU2002211654A1 (fr)
WO (1) WO2002031168A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010008168A (es) 2008-01-25 2011-02-24 P53 Inc Biomarcadores p53.
CA2832022C (fr) 2011-04-06 2019-01-08 Biovaxim Limited Compositions pharmaceutiques pour prevenir et/ou traiter une maladie provoquee par le vih chez des etres humains

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002355A1 (fr) * 1995-07-04 1997-01-23 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Virus mva recombinants et leur utilisation
WO1998054345A1 (fr) * 1997-05-30 1998-12-03 Baxter International Inc. Vecteur mini-adenoviral
WO1999008706A1 (fr) * 1997-08-14 1999-02-25 Commonwealth Scientific And Industrial Research Organisation Vecteur d'adenovirus de recombinaison porcin
WO2002008436A2 (fr) * 2000-07-20 2002-01-31 Genstar Therapeutics Corporation Système de vecteur mini-adénoviral pour vaccination

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002355A1 (fr) * 1995-07-04 1997-01-23 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Virus mva recombinants et leur utilisation
WO1998054345A1 (fr) * 1997-05-30 1998-12-03 Baxter International Inc. Vecteur mini-adenoviral
WO1999008706A1 (fr) * 1997-08-14 1999-02-25 Commonwealth Scientific And Industrial Research Organisation Vecteur d'adenovirus de recombinaison porcin
WO2002008436A2 (fr) * 2000-07-20 2002-01-31 Genstar Therapeutics Corporation Système de vecteur mini-adénoviral pour vaccination

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALAGUE C. ET AL.: "Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.", BLOOD, vol. 95, no. 3, 1 February 2000 (2000-02-01), pages 820 - 828, XP002216559, ISSN: 0006-4971 *
HINKULA J. ET AL.: "Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses", VACCINE, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 874 - 878, XP004075674, ISSN: 0264-410X *
NATUK R. J. ET AL.: "ADENOVIRUS VECTORED VACCINES", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, KARGER, BASEL, CH, vol. 82, 1994, pages 71 - 77, XP000973545, ISSN: 0301-5149 *
SVANHOLM C. ET AL.: "ENHANCEMENT OF ANTIBODY RESPONSES BY DNA IMMUNIZATION SUING EXPRESSION VECTORS MEDIATING EFFICIENT ANTIGEN SECRETION", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 228, no. 1/2, 1999, pages 121 - 130, XP000881871, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
WO2002031168A2 (fr) 2002-04-18
AU2002211654A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
WO1997045550A3 (fr) Vecteur mini-adenoviral
Addison et al. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors
AU696495B2 (en) Adenoviral vectors of animal origin and use in gene therapy
Li et al. Non-viral strategies for delivering genome editing enzymes
Hu et al. Design of retroviral vectors and helper cells for gene therapy
Cevher et al. Gene delivery systems: Recent progress in viral and non-viral therapy
EP1923467A3 (fr) Vecteurs d'adénovirus pour thérapie génétique
Mandl et al. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen
DK1224314T3 (da) Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
Babiuk et al. Adenoviruses as vectors for delivering vaccines to mucosal surfaces
BR9808147A (pt) Clone de ácido nucleico do vìrus da hepatite c (hcv) geneticamente engenheirado, clone plasmìdeo que abriga uma cdna do hcv de tamanho natural, dna ou rna do hcv transcrito do cdna do hcv de comprimento natural, linhagem de célula hospedeira transfectada e in vitro infectada com o hcv, animal não humano infectado com o hcv, partìcula viral do hcv, sistema de teste in vitro, isento de célula para o hcv, vacina do hcv e conjunto de teste para o hcv e processos para identificar uma linhagem de célula que é permissiva e um animal que é permissivo para a infecção por hcv, para selecionar hcv com mutações adaptativas que permitem nìveis mais altos de replicação do hcv em uma linhagem de célula permissiva, para infectar uma animal com o hcv, para propagar o hcv in vitro, para transduzir um animal suscetìvel à infecção por hcv com um gene heterólogo, para produzir partìculas virais do hcv, proteìnas de partìcula do hcv e anticorpos do hcv, para separar agentes capazes de modular a replicação do hcv, para preparar um ácido nucleico do hcv e para detectar anticorpos do hcv em uma amostra biológica de um paciente.
WO2000073478A3 (fr) Vecteurs adenoviraux recombinants pour l'infection specifique de cellules, l'integration de genomes et l'expression de proteines fibreuses chimeriques
US6399587B1 (en) Recombinant adenoviral vectors comprising a splicing sequence
DK0632129T3 (da) Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer
WO1999023216A3 (fr) Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci
DK0843731T3 (da) Adenovirusvektorer til genterapi
EP1298208A3 (fr) Ribozymes contre une séquence de Tat de HIV
Xue et al. Molecular engineering tools for the development of vaccines against infectious diseases: Current status and future directions
US20020155095A1 (en) Methods and compositions for delivery and expression of interferon-a nucleic acids
WO2002031168A3 (fr) Vaccins de recombinaison a mediation par adenovirus minimal
WO2003029433A3 (fr) Vecteurs viraux chimeres destines a une therapie genique
KR20000049243A (ko) 인터페론-알파 핵산의 운반 및 발현 방법 및 이를 위한 조성물
WO2000063406A3 (fr) Vecteurs adenoviraux possedant des acides nucleiques codant pour des molecules immunomodulatrices
Verdier et al. Preclinical safety evaluation of human gene therapy products.
CA2298064A1 (fr) Vecteurs adenoviraux chimeres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载